top of page


We provide innovative gene editing reagents and screening services for the global R&D market. Our success is based on the proprietary 3Cs technology developed at Goethe University’s Institute of Biochemistry II (IBC2). 

Vivlion is a spin-out of Goethe University Frankfurt am Main founded in December 2018 by a team of scientists together with Goethe University Frankfurt am Main as a shareholder. Seed funding was secured by a private equity company, gsccb Beteiligungsverwaltung GmbH.

Frank Junker
Chief Executive
Frank - 1_edited.jpg
Ivan Đikić
Co-Founder &
Advisory Chairman
Ivan Dikic CEO
Kerstin Koch
Co-Founder & Head Business Development
Kerstin Koch COO

Seasoned life-science professional with more than 20 years experience as business leader.

Renowned biomedical scientist and professor of Goethe University Frankfurt.

​Experienced project manager with background in life sciences and journalism.

Manuel Kaulich
Co-Founder &
Chief Technology Officer
Manuel Kaulich CSO_edited.jpg
Martin Wegner
Head of R&D and Customer Solutions
Martin - 1_edited_edited_edited_edited_e
Soenke Baestlein
Chief Financial Officer
Soenke - 1_edited_edited_edited_edited_e

Lead inventor of 3Cs technology and professor at Goethe University Frankfurt.

Venture capital investor, former senior partner in consulting and private equity.

Bioinformatician and co-developer of 3Cs technology and computational pipelines.

Vivlion is advised by representatives of Goethe University Frankfurt am Main and its technology transfer company Innovectis GmbH.

Goethe-Logo 4c.png

CRISPR gRNA library libraries 3Cs CRISPR/Cas Vivlion GmbH pooled arrayed CRISPR/Cas reagents screens validated products single multiplex multiplexing fixed-pair predefined combinations combinatorial screening

bottom of page